29
août
17h00
à
18h30
Conférence
Auditoire Paternot, Rue du Bugnon 25A, 1005 Lausanne

Prof. Richard Scolyer (Australia) Special Seminar

Publié par Progin Anne le 29.08.2019
Predicting Clinical Outcomes of Melanoma Patients

INVITATION

PREDICTING CLINICAL OUTCOMES OF MELANOMA PATIENTS

Thursday, 29th August 2019
AGORA
Auditoire Paternot, Rue du Bugnon 25A, 1005 Lausanne
17:00 – 18:30

Guest Speaker
Prof. Richard Scolyer (Australia)
© Bristol-Myers Squibb, 07/2019. 1506CH19PR02422-01
BMS contacts: Renée Carlberg, renee.carlberg@bms.com
Aurélie Benigno, aurelie.benigno@bms.com
Organized by Bristol-Myers Squibb
Sponsored by Roche
Richard Scolyer, independently ranked on multiple occasions as world’s leading melanoma pathologist
and one of world’s top melanoma researchers in any field /discipline, has an outstanding record of
research achievement. He leads an award winning translational research lab and has won multiple
prestigious awards for research excellence. Richard Scolyer is acknowledged internationally as an
expert / key-opinion leader in melanoma/translational research who focuses on melanoma clinical /
pathological diagnosis and treatment, biology of melanoma pathogenesis and response v’s resistance
to novel drug therapies. Richard Scolyer is staff specialist at a major teaching hospital and provides
pathology service to Melanoma Institute Australia (MIA) (world’s largest melanoma treatment centre)
and a clinical consultation service for pathological diagnosis of difficult pigmented lesions (> 2000 cases p. a. from throughout world). Richard
Scolyer is widely regarded as the point of reference for diagnosis of difficult pigmented lesions in Australasian region and beyond. Richard Scolyer
effectively integrates his clinical practice with leading award winning translational melanoma research laboratory. His record includes co-authoring
more than 500 publications including in prestigious journals.
Co-Medical

 Dernière mise à jour le 20/08/2019 à 16:10